The BMJ accuses drug company of withholding data on faulty test device in rivaroxaban trial - The Pharmaceutical Journal
CorConsult Rx - #Repost @ambcarerx ・・・ Oral Anticoagulants have many chronic indications, most commonly VTE treatment/prophylaxis, atrial fibrillation, and valvular heart disease. VTE & AF can both be treated with either warfarin
Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations | Perioperative Medicine | Full Text
Blood & Clots Series: How do I determine if my patient on a DOAC is still at increased risk of bleeding? - CanadiEM
POTD: COAGs and NOACs — Maimonides Emergency Medicine Residency
Xarelto® (rivaroxaban) - Recall, Warnings & Lawsuit Information
Practical Management of Patients receiving Rivaroxaban
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial - The Lancet Haematology
Xarelto: Package Insert - Drugs.com
Rivaroxaban: a fully-subsidised oral anticoagulant
Practical Management of Patients receiving Rivaroxaban
A) Switching from VKAs to rivaroxaban. (B) Switching from rivaroxaban... | Download Scientific Diagram
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
ROUND RED 20 xa Images - Xarelto - rivaroxaban - NDC 50458-575
RxNotes - It is important when switching between warfarin and DOACs (direct oral anticoagulation) to maintain adequate anticoagulation. 🇺🇸NOTE FOR USA: The American recommendations for switching from warfarin to rivaroxaban is INR <
Practical Management of Patients receiving Rivaroxaban
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Xarelto (rivaroxaban) Prescriber Guide
Skift fra Xarelto® til VKA | BERMITS Denmark
Treatment Considerations | XARELTO® (rivaroxaban) HCP
Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants - Priya Bhardwaj, Louise Breum Petersen, Tomas Sorm Binko, Jan Roland Petersen, Gitte Gleerup Fornitz, 2020
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
How to Switch From Warfarin to Xarelto - GoodRx
Xarelto® (rivaroxaban) – PIONEER
TMU-August 1995
